CSL was pleased to participate in and host a symposium at last week's Health Technology Assessment international (HTAi) annual meeting in Buenos Aires, Argentina. We joined fellow experts in discussing the essential role of plasma-derived medicinal products (PDMPs). Experts agreed that a resilient supply of PDMPs is a major imperative for patients of today and the future, recognizing that detrimental cost-containment policies and public procurement systems which prioritize price only, risk undermining the economic viability of these therapies with negative impacts over time. The unique nature of PDMPs — with the starting material coming from donated human blood plasma — combined with growing clinical demand, requires a thoughtful, tailored and multipronged policy approach. Better solutions are needed to ensure sustainable, steady supply and patient access. This symposium was a valuable opportunity to share insights about this special value chain and what it means for appropriate value recognition and access. At CSL, we are committed to enhancing and refining processes and policies to ensure reliable and sustainable access to PDMPs, which can ultimately contribute to better patient outcomes and alleviate pressure on healthcare systems. This is a core element of our promise to patients and the communities we serve. #HTAi2025 #PlasmaDerivedMedicinesProducts #PDMPs
Hear from Patients Who Rely on Plasma-Based Medicines
We share a TV news report about a mother and son who have a primary immune deficiency (PI).
CSL's 2025 Half Year Financial Results Click here for Full Information including Webcast Recording → | Would you like to read our 2024 Annual Report? Click here to view or download the Annual Report →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
CSL recently made an announcement about a new monoclonal antibody treatment. But what exactly are monoclonal antibodies? https://bit.ly/3IiugoA
💡 What if a congress booth could help change the world? At CSL Vifor, we believe every step matters — and that includes how we show up at congresses. This year at ERA, we were proud to be recognized as part of the association’s first-ever Green Meeting Certificate. It’s a clear signal that sustainability is becoming a shared priority across the industry. Our contribution? ✔️ A sustainable, modular, and reusable booth ✔️ A no-paper approach — everything available via QR code ✔️ A mindset of “not built to be destroyed” It’s all part of our long-term strategy to make kidney care — and the planet — better, one step at a time. 👉 Driven by our promise to improve kidney care, we’re committed to rethinking not just treatments, but how we engage. #SustainabilityInAction #CSLVifor #ERA2025 #GreenMeetings #OneStepAtATime #KidneyCare
Sustainability means more than reducing our footprint. At CSL, it also means expanding access to our therapies, supporting community health programs and partnering with organizations that improve care for those who need it most. Providing better care for brighter days ahead. #PromisingFutures #CSL Join us: https://bit.ly/4knsnnP